Kenneth Hoberman Sells 11,943 Shares of Stemline Therapeutics Inc (NASDAQ:STML) Stock

Stemline Therapeutics Inc (NASDAQ:STML) COO Kenneth Hoberman sold 11,943 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $14.18, for a total value of $169,351.74. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Kenneth Hoberman also recently made the following trade(s):

  • On Monday, December 18th, Kenneth Hoberman sold 11,983 shares of Stemline Therapeutics stock. The shares were sold at an average price of $14.18, for a total value of $169,918.94.

Shares of Stemline Therapeutics Inc (NASDAQ STML) traded up $0.25 during mid-day trading on Friday, reaching $14.10. The company had a trading volume of 100,595 shares, compared to its average volume of 208,878. The firm has a market capitalization of $352.75, a PE ratio of -5.49 and a beta of -0.02. Stemline Therapeutics Inc has a 52-week low of $5.50 and a 52-week high of $16.20.

Several analysts have recently commented on STML shares. BidaskClub raised Stemline Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, January 4th. HC Wainwright reissued a “buy” rating and issued a $38.00 price target on shares of Stemline Therapeutics in a report on Friday, November 10th. Cowen reissued a “buy” rating on shares of Stemline Therapeutics in a report on Tuesday, October 31st. Zacks Investment Research raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, January 5th. Finally, ValuEngine raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $33.75.

A number of hedge funds have recently modified their holdings of the stock. Empire Life Investments Inc. acquired a new position in Stemline Therapeutics during the third quarter worth $373,000. Cowen Inc. acquired a new position in Stemline Therapeutics during the third quarter worth $420,000. Lyon Street Capital LLC raised its holdings in Stemline Therapeutics by 331.1% during the third quarter. Lyon Street Capital LLC now owns 541,462 shares of the biopharmaceutical company’s stock worth $6,010,000 after purchasing an additional 415,867 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Stemline Therapeutics by 82.0% during the third quarter. Dimensional Fund Advisors LP now owns 219,252 shares of the biopharmaceutical company’s stock worth $2,434,000 after purchasing an additional 98,775 shares during the last quarter. Finally, C WorldWide Group Holding A S acquired a new position in Stemline Therapeutics during the third quarter worth $1,776,000. 50.24% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://ledgergazette.com/2018/01/13/kenneth-hoberman-sells-11943-shares-of-stemline-therapeutics-inc-stml-stock.html.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply